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Summary PS2, an oestrogen-inducible protein, was measured in the cytosol of 230 primary tumours from
patients who were subjected to first-line tamoxifen therapy for advanced disease without prior adjuvant
therapy with tamoxifen. PS2 correlated positively with oestrogen receptor (ER, P<0.01) and progesterone
receptor content (PgR, P<0.001), and with the length of progression-free survival (PFS, P = 0.05). Although
not statistically significant, higher levels of PS2 (> 1O ngmg-' protein) were also associated with increased
probability of response to tamoxifen treatment and a longer total post-relapse survival (PRS). ER, PgR,
menopausal status, site of disease and prior adjuvant chemotherapy were all associated with response to
tamoxifen therapy and with PFS. In multivariate analysis for PFS, low levels of ER and PgR, visceral
metastasis, a disease-free interval of less than 1 year and prior adjuvant chemotherapy were all significantly
associated with an increased probability of a rapid disease progression after start of tamoxifen therapy. In the
subset of 83 tumours with intermediate levels of ER and PgR (both > 10, but not both > 75 fmol mg'
protein), PS2 was positively related with the length of PFS (P<0.01) and PRS (P<0.05). PS2 remained the
strongest factor in multivariate analysis for PFS (P<0.01) in this ER/PgR intermediate subgroup, but was not
of predictive value in univariate or multivariate analysis for both PFS and PRS in tumours classified as
ER/PgR low or high ( > 75 fmol mg-' protein). It is concluded that PS2 status may be used as a parameter,
additional to ER and PgR, for better refinement of prediction of response to tamoxifen treatment in advanced
breast cancer patients especially with intermediate ER/PgR levels in their primary tumour.
It is generally acknowledged that the presence of the oes-
trogen receptor (ER) and progesterone receptor (PgR) in
primary breast tumour biopsies indicates a relatively good
prognosis regarding relapse-free survival and overall survival.
In addition to ER and PgR, a large variety of other prognos-
tic factors, including patient characteristics, blood parameters
and tumour cell biological factors, have been described (see
for reviews, Klijn & Foekens, 1990; McGuire & Clark, 1992;
Gasparini et al., 1993). Only a few of the many new variables
have been evaluated with respect to response to hormonal
therapy or chemotherapy in recurrent disease (see for
reviews, Gasparini et al., 1993; Klijn et al., 1993). ER status,
and later also PgR status, have been shown to define those
patients with advanced breast cancer who are likely to benefit
from endocrine therapy (Osborne et al., 1980; Horwitz et al.,
1985). However, the presence of ER or PgR in a breast
tumour does not fully predict those patients who are likely to
benefit from endocrine therapy, and only about one-half of
the patients with steroid receptor-positive tumours will re-
spond to anti-oestrogen therapy. One of the reasons may be
the presence of aberrant ER not functioning properly in cell
signalling (Sluyser & Mester, 1985; Fuqua et al., 1993a;
Horwitz, 1993). Indeed, ER variants that are unable to bind
DNA have been described in non-responding ER-positive
patients (Scott et al., 1991). In addition, ER variants can
interfere with wild-type ER DNA binding in a dominant
negative manner (Fuqua et al., 1992), not as a result of
mutations within the DNA binding domain (Fuqua et al.,
1993b).
It has been hypothesised that the measurement of
oestrogen-regulated proteins, such as PgR (Horwitz et al.,
1975) and pS2 protein (Rio et al., 1987), may provide a more
accurate assessment of functional ER activity and likelihood
of response to endocrine therapy. The pS2 protein (PS2) is a
small secretory protein with a molecular weight of 7kDa
(Nunez et al., 1987) with an as yet unknown function and
which is induced by oestradiol in ER-positive breast cancer
cells (Masiakowski et al., 1982). Rio et al. (1987) have shown
that PS2 expression is predominantly associated with ER
positivity. The cytosolic content of PS2 in primary breast
tumour biopsies has recently been shown to be a marker of
favourable prognosis regarding response to adjuvant hor-
monal therapy (Predine et al., 1992), and time to relapse and
death (Foekens et al., 1990, 1993; Predine et al., 1992; Gion
et al., 1993). Similar results with respect to a relationship
between PS2 expression and (relapse-free) survival were
obtained when PS2 transcripts were analysed (Thompson et
al., 1993). On the other hand, immunohistochemically
assessed PS2 status was of no or only marginal prognostic
value (Henry et al., 1991; Cappelletti et al., 1992; Thor et al.,
1992). In pilot studies involving 21 patients with recurrent
disease, PS2 at the transcriptional level was predictive for
endocrine responsiveness (Henry et al., 1989; Skilton et al.,
1989). Similar results were obtained with immunohisto-
chemically assessed PS2 status in small series of 35 (Henry et
al., 1991) and 72 patients (Schwartz et al., 1991), but these
findings were not confirmed by Luqmani et al. (1993a) in a
study involving 70 patients.
After our preliminary analysis (Klijn et al., 1992), in the
present study concerning 230 patients who developed recur-
rent disease, we aimed to assess whether, together with ER
and PgR status, cytosolic PS2 is able to identify patients who
are likely to benefit from first-line tamoxifen therapy.
Patients and methods
Patients and tumour samples
In order to evaluate the clinical significance of PS2 in
advanced disease, we have selected a series of 230 breast
cancer patients who underwent primary tumour resection
between 1980 and 1988 according to the following criteria:
patients must have undergone primary surgery in or been
referred to our centre for (adjuvant) radiotherapy of the
primary tumour or for treatment of advanced disease; frozen
primary tumour must be available in the tumour bank (liquid
nitrogen); and the patients must have developed recurrent
disease during follow-up and be subjected to first-line hor-
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monal therapy (tamoxifen, 40 mg day-'). Furthermore, the
patients must not have had adjuvant hormonal therapy,
neoadjuvant therapy or prior chemotherapy for advanced
disease. The mean age of the patients was 62 years, range
33-91 years. After primary surgery, 38 patients (17%) had
received systemic adjuvant chemotherapy, mainly CMF (cy-
clophosphamide, methotrexate, 5-fluorouracil). During the
period of metastatic disease, 47% of the patients were subse-
quently treated with one or more additional hormonal
treatments (mostly progestins) after progression on the first-
line tamoxifen treatment. After occurrence of resistance to
hormonal therapy, 104 patients (45%) have so far received
additional chemotherapy (mainly CMF). Seventy-five
patients were still alive at a median follow-up time of 19
months (range 5-58 months) and 155 patients have died with
a median survival time of 13 months. During follow-up after
start of first-line endocrine therapy most patients (202/230)
developed tumour progression with a median time to pro-
gression of 153 days (mean 273 days; range 9 days to 7
years). During hormonal therapy patients were reviewed at
the out-patients clinic on average once every 6 weeks, during
long-term remission up to once every 12 weeks. During
chemotherapy patients were seen at regular intervals depend-
ing on the treatment scheme (intervals not longer than 3
weeks). Standard criteria for response were used, i.e. for
complete response (CR) a complete disappearance of all
metastases; for partial response (PR) a decrease of more than
50%; and for progressive disease (PD) an increase of more
than 25% of the tumour size or the occurrence of new
lesions. Stable disease (SD) indicates a status in between PR
and PD. In the analysis for response to therapy (yes/no),
response was defined as CR, PR or a SD longer than 6
months, as described by Ravdin et al. (1992). In case of
doubt, the worse type of response was chosen. This use of
strict criteria might explain the relatively low objective re-
sponse rates in our study. However, in view of the retrospec-
tive character of this study, we regarded progression-free
survival (PFS) and post-relapse survival (PRS) as the main
end points for this study. The length of PFS was defined as
the timespan from the start of treatment until the start of the
next treatment or time of death. Time till progression for
patients with initial slowly progressive disease or who
occasionally were treated for 4 or 5 months was set at 3
months.
Oestrogen receptor (ER), progesterone receptor (PgR) and
PS2 assays
Tissue was pulverised in the frozen state and homogenised,
and cytosolic ER and PgR levels were determined within 1
month after surgery with radioligand binding assays as
recommended by the EORTC (EORTC Breast Cancer
Cooperative Group, 1980), and as described previously
(Foekens et al., 1989). Cytosolic PS2 was measured by
radiometric immunoassay kits (ELSA-PS2 kits, kindly pro-
vided by CIS bio international, Gif-sur-Yvette, France) as
described previously (Foekens et al., 1993). All laboratory
measurements were performed by technicians unaware of
treatment outcome. In addition, the clinicians evaluating the
clinical data were not aware of the laboratory results.
Statistics
The associations between ER, PgR and PS2 were studied
with scatterplots (not shown) and Spearman rank correla-
tions. The two-sample Wilcoxon rank-sum test was applied to
test equality of medians. Logistic regression analysis was
used for the analysis of response, while Cox regression
analysis was used for the analysis ofPFS and PRS. Variables
included in the multivariate analyses were ER, PgR, PS2,
age, menopausal status, tumour size, nodal status, disease-
free interval between primary surgery and time of relapse,
adjuvant chemotherapy and site of metastasis. In the case of
multiple sites the lowest score (worst prognosis) was taken.
PFS and PRS curves were computed with the method of
Kaplan and Meier. The log-rank test was applied to test for
differences between two groups in PFS or PRS. The Cox
model was used to test for trend. All analyses were restricted
to the first 2 years or follow-up because ofthe low number of
patients in the tail of the PFS curves after 2 years.
Results
Patient characteristics
The characteristics of the patients are listed in Table I. The
majority of the patients were post-menopausal, had larger
tumours and were node positive at time of primary surgery.
The relatively large number of patients with node-positive
disease and large (T3,4) tumours, as compared with the
general population of patients with primary breast cancer, is
probably due to the selection of only patients who developed
metastatic disease and to the association of tumour size and
nodal status with risk for metastasis. Fourteen per cent of the
patients already had metastatic disease at the time of their
original diagnosis (disease-free interval of 0). Seventeen per
cent of the patients had prior adjuvant chemotherapy. About
one-third of the patients who received first-line tamoxifen
therapy had primary tumours with ER and/or PgR levels
below 10 fmol mg-' protein.
Response to treatment
Of the 230 patients, 41 (18%) showed an objective response
(CR, n = 9; PR, n = 32), 66 (29%) showed a stable disease
(SD) of >6 months, 16 (7%) a SD of <6 months, while 107
Table I Patient characteristics
Number of
Patient group patients %
All patients 230 100
Menopausal status
Premenopausal 45 20
Post-menopausal 185 80
Age (years)
<65 126 55
>65 104 45
Nodal status
NO 55 26
N1-3 55 26
N>3 105 49
Tumour size (cm)
TI ( 2) 47 22
T2 (2-5) 105 50
T3 (>5) 31 15
T4 29 14
ER level (fmol mg-' protein)
<10 40 17
10 190 83
PgR level (fmolmg-' protein)
<10 77 34
)10 152 66
Disease main site
Visceral 89 39
Bone 102 44
Soft tissue 39 17
Disease-free interval
0 33 14
<1 year 60 26
1-2 years 77 33
>2 years 60 26
Prior adjuvant therapy
Yes 38 17
No 192 83
aOwing to missing information numbers do not always
230.
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patients showed progressive disease (PD). Median time to
progression of patients with a CR was 85.1 months. The rate
of progression of patients with a SD of > 6 months was not
different from that of patients with a PR (median PFS, 12.6
and 13.8 months respectively), whereas patients with a SD
<6 months by definition experienced a disease progression
between 3 and 6 months (median 5.0 months). Median PFS
of patients with PD was 2.5 months.
The median post-relapse survival time (PRS) from start of
tamoxifen therapy was 102.9 months for patients with CR,
29.5 months for patients with a PR and 32.2 months for
patients with SD >6 months, while median PRS was 9.8
months for patients showing PD and 17.5 months for
patients with a SD <6 months. Similar to the criteria used
by Ravdin et al. (1992), in the present study we have defined
response as CR + PR + SD >6 months. Figure 1 shows, for
patients with CR, PR, SD >6 months, SD <6 months and
PD, the Kaplan-Meier curves for 2-year PRS.
Levels ofPS2 and associations with ER, PgR, andpatient
characteristics
The median PS2 level was 7.2 ngmg-' protein (range
0-599 ng mg-' protein; mean ± s.d., 37 ± 74 ng mg-' pro-
tein). The level of PS2 was positively correlated with those of
ER (Rs = 0.19, P<0.01) and of PgR (Rs = 0.23, P<0.001).
PS2 was not correlated with menopausal status or age of the
patient or with disease-free interval (DFI). PS2 levels were
not different in the primary tumours of patients who had had
prior adjuvant chemotherapy as compared with those who
had had no adjuvant treatment. The disease site was cor-
related with tumour levels of PS2 (P<0.02); primary
tumours which later metastasised to the bone had higher PS2
levels (median 12.1 ng mg-' protein) than those that meta-
stasised to visceral sites or to soft tissues (4.3 and
3.2 ng PS2 mg-' protein respectively).
Tumours of patients responding to tamoxifen as compared
with non-responding patients had 3.0-fold higher median
levels of ER (P<0.001), 2.9-fold higher levels of PgR
(P<0.001), and 2.2-fold higher median levels of PS2
(P = 0.09).
ER, PgR and PS2, and response to tamoxifen therapy
For tumours with ER or PgR levels equal or above the
widely used threshold value of 1Ofmol mg-' protein, logistic
regression analysis for trend of log transforms of ER and
PgR values showed that there was still a significant associa-
tion of steroid receptor levels (P=0.002 and P=0.005,
respectively) with the rate of response (CR + PR + SD >6
months). Therefore it was investigated whether an additional
cut-off value for ER and/or PgR could be considered. Based
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Figure 1 Actuarial post-relapse survival for patients with
different types of response to tamoxifen therapy CR, complete
responders (. . . ); PR, partial responders ( ); SD > 6 months,
stable disease for more than 6 months (---); SD <6 months,
stable disease for less than 6 months (-----); PD, progressive
disease (---). Numbers between parentheses represent failures/
total number of patients in each group.
on isotonic regression analysis with the length of PFS as end
point, 75 fmol mg-' protein was chosen as cut-off point for
both ER and PgR in addition to 10 fmol mg-' protein. Table
II shows the response rates to tamoxifen based on tumour
ER and PgR levels <10 fmol mg-' protein, with levels
between 10 and 75 fmol mg-' protein, and with levels
.75 fmol mg-' protein. For ER the response rate increased
from 25% to 63%, and for PgR from 38% to 62%. From a
clinical point of view, relevant subgroups could be those with
one or both receptors <10 fmolmg-1 protein (defined as
ER/PgR low), those with both >75 fmol mg-' protein (ER/
PgR high), and those with both . 10 but not both
>75 fmol mg-' protein (ER/PgR intermediate). The re-
sponse rates increased from 34% for patients with ER/PgR
low tumours, via 45% for ER/PgR intermediate tumours, to
66% for patients with ER/PgR high tumours (P<0.001,
Table II).
In logistic regression analysis for trend there was no
significant association between the level of PS2 and the rate
of response. A search for an optimised cut-off point for PS2
was considered unjustified. Tumours were therefore arbit-
rarily divided in three groups. The group with the lowest PS2
levels was defined as those with levels <2 ng mg' protein,
the previously defined cut-off point in analysis for relapse-
free survival in primary breast cancer (Foekens et al., 1993).
The other groups were defined as those having levels
10 ng mg' protein, which is the median PS2 level of the
ER/PgR intermediate and high tumours (as compared with
1.2 ngmg-' protein of the ER/PgR low group), and a group
with PS2 levels in between. The highest response rate (53%)
was observed for patients with PS2 levels > 10 ng mg-' pro-
tein, although this response rate did not significantly differ
Table II Response rates to tamoxifen correlated with clinical and
cytosolic variables
Number of Per cent
Patient subgroup patients responding P-value
All patients 230 47a
Menopausal status
Premenopausal 45 31 <0.05
Post-menopausal 185 50
Age (years)
<65 126 42 0.14
.65 104 52
ER level (fmol mg ' protein)
<10 40 25 <0.001
10-75 75 32
.75 115 63
PgR level (fmol mg' protein)
<10 77 38 <0.005
10-75 76 39
.75 76 62
ER/PgR levelb
Low 87 34 <0.001
Intermediate 83 45
High 59 66
PS2 level (ngmg-' protein)
<,2 93 43 0.20
>2- 10 37 38
. 10 100 53
Disease main site
Visceral 89 38 <0.05
Bone 102 48
Soft tissue 39 62
Disease-free interval
0 33 39 <0.05
<1 year 60 35
1-2 years 77 52
>2 years 60 55
Prior adjuvant chemotherapy
Yes 38 26 <0.01
No 192 51
'Of the 107 responding patients, nine had a CR, 32 a PR and 66 a
SD >6 months. bLow, one or both <10 fmol mg' protein;
intermediate, both .10 fmolmg' protein, but not both
>75 fmolmg-' protein; high, both .75 fmol mg-' protein.1220 J.A. FOEKENS et al.
from those observed for the other two groups with lower PS2
levels (Table II).
Table II furthermore shows that, in univariate analysis,
post-menopausal patients experienced a more favourable re-
sponse rate to tamoxifen treatment than premenopausal
patients, while age did not contribute any further, and that
soft-tissue and bone metastases showed a higher response
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Figure 2 Actuarial progression-free (top) and post-relapse sur-
vival (bottom) for patients with (thin lines) and without (bold
lines) prior adjuvant chemotherapy. Numbers between paren-
theses represent failures/total number of patients in each
group.
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rate than visceral metastases. A positive trend was observed
regarding disease-free interval and response to tamoxifen
therapy. Patients who received prior adjuvant chemotherapy
showed a 2-fold lower response rate (P<0.01) to tamoxifen
therapy of metastatic disease than patients who received no
prior adjuvant treatment (Table II). Moreover, the length of
PFS and PRS following tamoxifen treatment turned out to
be significantly shorter among patients who had received
prior adjuvant chemotherapy (P<0.002 and P<0.02 respec-
tively; Figure 2).
ER, PgR, and PS2 and association with PFS and PRS
The Kaplan-Meier curves for PFS and PRS based on the
combined ER/PgR status (left panels) and PS2 status (right
panels) are shown in Figure 3. High levels of ER and PgR
were associated with a longer PFS and PRS, whereas low or
intermediate ER/PgR levels were associated with a more
rapid disease progression and death. The PFS curves con-
verged after 2 years, whereas the PRS curves converged only
after approximately 4 years (not shown). High levels of PS2
(10 ng mg' protein) were also associated with an in-
creased PFS and PRS, although these associations were
weaker and in analysis of both PFS and PRS the curves
converged after 2 years (Figure 3).
In the relatively large subgroup of 83 patients (= 36%)
defined as ER/PgR intermediate, which showed an approxi-
mately equally short PFS and PRS following tamoxifen
therapy as compared with those defined as ER/PgR low
(Figure 3), a high level of PS2 was significantly associated
with a prolonged PFS (P<0.01) and PRS (P<0.05). In this
subgroup of tumours with ER/PgR intermediate levels, a
high level of PS2 was able to identify those patients with a
similar favourable PFS and PRS as those in the ER/PgR
high group. In addition, a low level of PS2 could identify
patients with a comparable short PFS and PRS as those in
the ER/PgR low group (Figure 4 as compared with Figure 3,
left panels). In the subgroups defined as ER/PgR low and
ER/PgR high, the Kaplan-Meier curves for PFS and PRS
stratified by PS2 were superimposable (not shown).
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Figure 3 Actuarial progression-free (top) and post-relapse survival (bottom) stratified by combined ER/PgR status (left) and PS2
status (right). ER/PgR high (bold lines), both > 75 fmol mg-' protein; ER/PgR-interim. (dotted lines), both > 10 fmol mg-', but
not both >75fmolmg-' protein; ER/PgR low (thin lines), one or both <10fmolmg-' protein. PS2 high (bold lines),
> 10 ngmg'l protein; PS2 low (thin lines), <10 ngmg'l protein. Numbers between parentheses represent failures/total number of
patients in each group.
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Cox multivariate regression analysisfor PFS andPRS
In Cox multivariate regression analyses for PFS and PRS,
ER, PgR and PS2 were included together with age and
menopausal status, site of metastasis, DFI, size of the
primary tumour, nodal status at surgery of the primary
tumour and prior adjuvant chemotherapy. In Table III the
results of the final Cox multivariate regression analyses for
both PFS and PRS are listed. Prior adjuvant chemotherapy
was significantly associated with both an early tumour pro-
gression (relative hazard rate, RHR 2.29) and an early death
(RHR 3.01) after start of tamoxifen therapy for advanced
disease. Similarly, visceral metastases were associated with a
short PFS (RHR 1.48) and PRS (RHR 2.55). A DFI of more
than 1 year was associated with a longer PFS (RHR 0.72),
whereas younger patients (<65 years) experienced an earlier
death (RHR 1.68). High levels of ER and PgR were
associated with a longer PFS (RHR 0.48) and PRS (RHR
0.42). When analysed as a dichotomised or as a continuous
variable, PS2 did not contribute significantly to the mul-
tivariate models for PFS and PRS for all patients (data not
shown).
Separate Cox multivariate analyses for PFS and PRS were
performed in the subgroup of 83 tumours defined as ER/PgR
intermediate. PS2 was entered as a dichotomised variable
( 10 vs <10 ng mg-' protein). After correction for all other
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Figure 4 Actuarial progression-free (top) and post-relapse sur-
vival (bottom) for patients with intermediate ER/PgR tumour
levels stratified by PS2. PS2 high (bold lines), > 10 ng mg-'
protein; PS2 low (thin lines), <10ngmg-' protein. Numbers
between parentheses represent failures/total number of patients in
each group.
factors as entered in the models presented in Table III, in this
subgroup of ER/PgR intermediate tumours, a high level of
PS2 was associated with a shorter PFS (RHR 0.51, P<0.01)
and a shorter PRS (RHR 0.63), the latter not statistically
significant (P = 0.13).
Discussion
For refinement of the selection of therapy, it would be
beneficial to have other factors available, additional to ER
and PgR, which could more reliably identify those patients
likely to respond or fail to respond to endocrine therapy of
advanced breast cancer. One candidate factor could prove to
be PS2, a protein which is secreted by breast cancer cells in
vitro upon oestrogen stimulation (Masiakowski et al., 1982;
Nunez et al., 1987). Indeed, in a few pilot studies involving
up to 72 patients, PS2 transcripts (Henry et al., 1989; Skilton
et al., 1989) and immunohistochemically assessed PS2 status
(Henry et al., 1991; Schwartz et al., 1991) were reported to be
predictive for endocrine responsiveness of advanced breast
cancer. However, no consensus exists regarding immuno-
histochemically assessed PS2 status (Luqmani et al., 1993a).
In only two studies described so far, PS2 status has been
studied in relation to duration of post-relapse survival and/or
duration of response, but no association was found (Henry et
al., 1989; Schwartz et al., 1991).
Higher levels of PS2, measured by immunoassays in breast
tumour cytosols, have shown to be associated with an in-
creased length of relapse-free and overall survival in primary
breast cancer (Foekens et al., 1990, 1993; Predine et al., 1992;
Gion et al., 1993) and a more favourable response to
adjuvant hormonal therapy (Predine et al., 1992). However,
no information is currently available in the literature regar-
ding cytosolic PS2 levels and response to endocrine therapy
for advanced disease. Irrespective of the technique used to
assess PS2, as in the present study, the expression of PS2 in
human primary breast tumours has shown to be correlated
with that of ER or PgR (Rio et al., 1987; Henry et al., 1989,
1991; Skilton et al., 1989; Foekens et al., 1990, 1993;
Schwartz et al., 1991; Cappelletti et al., 1992; Koerner et al.,
1992; Predine et al., 1992; Thor et al., 1992; Gion et al.,
1993; Luqmani et al., 1993b; Thompson et al., 1993).
In the present study, PS2 was quantitatively assessed in
cytosols of a relatively large number of 230 tumours. The log
of PS2 showed a positive association with the probability of
response and PFS, but these associations were not very
strong and not statistically significant. To enable visualisation
of the effects of PS2 on progression-free survival (PFS) and
post-relapse survival (PRS), and for reasons of more con-
venient data analyses, we have chosen to dichotomise PS2
values at 1Ong mg' protein, which was the median value in
tumours not belonging to the subgroup with low ER and/or
PgR levels. Patients with high tumour levels of PS2
experienced a prolonged PFS and PRS, although the associa-
tions were weak and of borderline or no statistical significance
(Figure 3). From the results listed in Table II and shown in
Figure 3, it can be concluded that tumours with intermediate
ER/PgR levels respond approximately equally poorly to
Table III Cox multivariate analysis for progression-free and post-relapse survivala
Progression-free survival Post-relapse survival
RHR (95% CL)b P-value RHR (95% CL)b P-value
Agec 1.05 (0.75-1.45) 0.76 1.68 (1.12-2.51) 0.01
Disease-free intervald 0.72 (0.53-0.98) 0.04 0.71 (0.48-1.03) 0.07
Visceral metastasise 1.48 (1.10-2.00) <0.01 2.55 (1.78-3.66) <0.001
ER/PgRf 0.48 (0.34-0.68) <0.001 0.42 (0.26-0.66) <0.001
Adjuvant therapyg 2.29 (1.45-3.42) <0.001 3.01 (1.74-5.21) <0.001
aThe models included 229 patients. Tumour size, nodal status and menopausal status did
not significantly contribute to the models. bRHR (95% CL): relative hazard rate (95%
confidence limits). cAge: <65 years versus > 65 years. dDisease free interval: > 1 year
versus <1 year. 'Visceral metastasis: yes versus no. fER/PgR-high (both >75 fmol mg-'
protein versus ER/PgR intermediate and ER/PgR low. gAdjuvant therapy: prior adjuvant
chemotherapy, yes versus no.1222 J.A. FOEKENS et al.
tamoxifen therapy as those having low ER/PgR levels.
Therefore, it is questionable whether patients with this ER/
PgR intermediate phenotype, a relatively large group of
tumours (36% of the total number of patients), should be
treated with tamoxifen based on ER and PgR values alone.
Interestingly, in the exploratory analyses shown in Figure 4,
the predictive effect of PS2 in analyses for PFS (P<0.01)
and PRS (P<0.05) was exclusively present in the subgroup
of tumours with intermediate ER and PgR levels (also in
multivariate analysis for PFS), and not in the subgroups with
low or high ER and PgR values. In this subgroup, PS2
identified patients with a good and poor prognosis, such that
tumours with low PS2 levels behaved similarly to those with
low ER/PgR levels and tumours with high PS2 levels per-
formed comparably well as those having both high ER and
PgR levels.
In the present study PS2 status as determined by quanti-
tative immunoassay in cytosolic extracts had less predictive
power than ER or PgR status. These data are in agreement
with those of Luqmani et al. (1993a), who used immuno-
histochemically assessed ER, PgR and PS2 in a series of 70
patients. On the other hand, Henry et al. (1991) in a study
involving 35 patients, and Schwartz et al. (1991) in a study
involving 72 patients, found immunohistochemically assessed
PS2 positivity to be a stronger predictive factor for response
to endocrine therapy than ER. Moreover, PS2 mRNA ex-
pression was found to be a stronger predictive factor for
response to tamoxifen therapy than ER mRNA expression in
a study involving 21 patients (Henry et al., 1989), whereas
Skilton et al. (1989) in a series of 21 patients reported an
equal response rate when analysing PS2 mRNA expression
and ER expression determined by ligand-binding assay or by
immunohistochemistry. The low number of patients in the
various studies and the different techniques used to assess
PS2 status most likely caused the discrepancies between the
results obtained.
ER and also PgR levels were found to be significantly
predictive for response (Table II) duration of response
(Figure 3) and length of post-relapse survival (Figure 3) after
the start of tamoxifen therapy for advanced disease. In addi-
tion, we found that the higher the levels of ER or PgR, the
higher the likelihood of a response, and consequently longer
PFS and PRS. Cox regression models of PFS and PRS
showed that after correction for the effect of other prognostic
indicators, ER and PgR remained as significant independent
variables. Similar results were recently reported by Ravdin et
al. (1992) describing a prospective evaluation of PgR in
ER-positive breast cancer patients treated with tamoxifen.
The overall response rate (CR, PR and SD >6 months) in
this study, involving also 40 (17%) patients with tumours
containing ER levels <10 fmol mg-', was 47%. This is
similar to the overall response rate of 54% reported by
Ravdin et al. (1992) using the- same response criteria in a
study involving only patients with ER levels more than
3 fmol mg-l protein. Similarly, the lower response rate in
premenopausal patients as compared with post-menopausal
patients in our study (30% vs 50%) was similar to that
reported by Ravdin et al. (1992) (24% vs 57%). This low
response rate in premenopausal patients may be due to the
lower percentage of tumours with ER levels >75 fmol mg-'
protein as compared with tumours of post-menopausal
patients (27% vs 56%, P<0.001) in the present study. As a
result of the stronger contribution of ER in the multivariate
models for PFS and PRS, menopausal status was not an
independent variable.
Interestingly, patients with a DFI of less than 1 year
showed a lower probability and shorter duration of response,
a finding also described by Ravdin et al. (1992). The reason
for this is currently unclear but might have a biological basis,
i.e. that rapidly relapsing tumours have a more aggressive
phenotype and as result are subsequently prone to treatment
failure once metastasised. In contrast to the study of Ravdin
et al. (1992), in the present study the site of disease, parti-
cularly visceral metastasis, was a significant predictor of
lower probability of response to therapy and a shorter PFS
and PRS. This was not because in our study the primary
tumours of patients who developed visceral metastases had
lower ER or PgR levels which could explain the lower re-
sponse rates. Moreover, the association of visceral metastasis
with PFS and PRS was also present in the multivariate
models presented in Table III.
Of 38 patients who had received adjuvant chemotherapy,
only 26% responded, as compared with 51% of the patients
who did not receive adjuvant treatment (Table II). Conse-
quently, patients who had received adjuvant treatment
experienced a significantly shorter PFS and PRS (Figure 2) in
multivariate analyses also (Table III). These observations were
not made by Ravdin et al. (1992), but were observed by
others (for review see, Rubens et al., 1994), and a 2-fold
difference in response was also obtained by the Guy's Hos-
pital, as reviewed by Rubens (1993). Moreover, a shorter
PFS and PRS were observed, although the relationship
between prior adjuvant chemotherapy and shorter PRS was
not statistically significant since the curves converged with
time (Rubens, 1993). A similar pattern of the survival curves
with time has also been reported by de Takats et al. (1993).
The observation that patients who received adjuvant treat-
ment respond worse to subsequent tamoxifen therapy on
relapse may suggest that prior chemotherapy caused a selec-
tion of specific tumour cells with an altered hormone recep-
tor phenotype in the occult tumours, possibly by chemical
castration. Nevertheless, for the overall group of primary
breast cancer patients the results of the meta-analysis (Early
Breast Cancer Trialists' Collaborative Group, 1992) indicate
that the positive benefit on overall survival is not overriden
by shortened post-relapse survival in patients with relapse.
From the current study we conclude that, as compared
with PS2, cytosolic ER and PgR are stronger markers to
predict response, duration of response and length of post-
relapse survival on tamoxifen therapy for advanced disease.
In addition to ER and PgR, PS2 status may, however, be
helpful in defining those patients with intermediate ER and
PgR levels who are likely to benefit from tamoxifen therapy.
Further prospective studies are necessary before coming to
firm conclusions on the usefulness of PS2 as an additional
marker to predict the hormonal responsiveness of advanced
breast cancer.
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